Varoglutamstat - Vivoryon Therapeutics
Alternative Names: PQ-912; SIM 0408; SIM-0801Latest Information Update: 23 Jul 2024
At a glance
- Originator Probiodrug
- Developer University of California, San Diego; Vivoryon Therapeutics
- Class Anti-inflammatories; Antidementias; Benzimidazoles; Imidazolidines; Neuroprotectants; Small molecules
- Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease; Diabetic nephropathies
- No development reported Huntington's disease; Inflammation
Most Recent Events
- 18 Jul 2024 Efficacy and adverse events data from a phase IIb VIVIAD trial in Diabetic-nephropathies subgroup released by Vivoryon Therapeutics
- 18 Jul 2024 Vivoryon Therapeutics plans a phase II trial for Diabetic nephropathies
- 23 May 2024 Varoglutamstat - Vivoryon Therapeutics is available for licensing as of 23 May 2024